** Shares of VYNE Therapeutics VYNE.O plummet 72% to an all-time low of 40 cents
** Stock set for its worst day in over 7 years, if losses hold
** Co says its skin disease drug, Repibresib gel, for vitiligo failed to meet its mid-stage trial goals, of improving facial vitiligo by at least 50% or 75%
** VYNE will halt the trial's ongoing extension phase and seek an external partner to continue developing Repibresib
** Repibresib gel caused more mild skin side effects and application site pain than placebo, co says
** Co had about $39.6 million in cash as of June 30
** Including session's move, stock down 88% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。